Xeris Biopharma Holdings (XERS) Accounts Payables (2020 - 2026)

Xeris Biopharma Holdings has reported Accounts Payables for 7 years, with the latest figure at $11.5 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 80.53% year-over-year to $11.5 million; the trailing twelve-month figure through Mar 2026 stood at $11.5 million (up 80.53% YoY), and the FY2025 full-year result was $3.1 million, up 34.32% from the prior year.
• Accounts Payables for Q1 2026 stood at $11.5 million, up from $3.1 million in the prior quarter.
• The five-year high for Accounts Payables was $12.1 million in Q3 2023, with the low at $2.3 million in Q4 2024.
• Historically, Accounts Payables has averaged $7.8 million across 5 years, with a median of $7.1 million in 2024.
• Annual changes were most pronounced in 2023 — Accounts Payables soared 208.43% — and 2024, when it sank 80.2%.
• Xeris Biopharma Holdings' Accounts Payables stood at $4.6 million in 2022, then jumped by 151.09% to $11.6 million in 2023, then slumped by 80.2% to $2.3 million in 2024, then soared by 34.32% to $3.1 million in 2025, then jumped by 272.79% to $11.5 million in 2026.
• The last three Accounts Payables figures came in at $11.5 million (Q1 2026), $3.1 million (Q4 2025), and $6.5 million (Q3 2025), per Business Quant data.